HOME >> BIOLOGY >> NEWS
Schizophrenia gene variant linked to risk traits

Researchers at the NIH's National Institute of Mental Health (NIMH) have identified a relationship between a small section of one gene, the brain chemical messenger glutamate, and a collection of traits known to be associated with schizophrenia. The finding confirms the gene responsible for management of glutamate is a promising candidate in determining risk for schizophrenia. The study, conducted by Michael Egan, M.D., Daniel Weinberger, M.D., and colleagues, will be in the August 24th issue of the Proceedings of the National Academy of Sciences, published online the week of August 9, 2004.

Glutamate is a key neurotransmitter long thought to play a role in schizophrenia. The gene identified in this study makes the glutamate receptor (GRM3) which is responsible for regulating glutamate in synapses--spaces in between brain cells--where chemicals like glutamate transfer information from cell to cell. The amount of glutamate remaining in the synapse may have a downstream impact on cognition.

"Because of the small effects of individual genes in complex genetic disorders like schizophrenia, it is difficult to make significant associations with any one particular marker. However, this study brings us closer to unlocking the genetic clues that increase the risk for schizophrenia," said NIMH Director Thomas R. Insel, M.D.

Researchers know that schizophrenia affects several regions in the front part of the brain that are involved in higher order thinking and decision-making and neurotransmitter systems like glutamate. Many of the genes already identified as likely candidates for the disorder have been thought to affect the glutamate system. The study implicates the GRM3 gene as well.

GRM3 alters glutamate transmission, brain physiology and cognition, increasing the risk for schizophrenia. To pinpoint the section of the gene responsible for these changes, scientists are exploring a region where the gene may differ by one letter at a location c
'"/>

Contact: Jennifer Loukissas
nimhpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
12-Aug-2004


Page: 1 2 3

Related biology news :

1. Schizophrenia and bipolar disorder could have similar genetic causes
2. Schizophrenia research links form and function
3. Schizophrenia possibly linked to early brain development
4. Study Shows First Significant Genetic Evidence For Schizophrenia Susceptibility
5. Hallucinations In Schizophrenia: Genetic Findings
6. The Genetic Basis Of Childhood Schizophrenia
7. Husband-And-Wife Team Embarks On Search For Genes Linked To Schizophrenia
8. Testosterone And Working Memory; Epilepsy And Schizophrenia; Toxins And Neuron Death; Oregon Researchers Present Findings At Society For Neuroscience
9. Gene-Altered Mouse May Provide New Insights To Parkinsons Disease, Substance Abuse And Schizophrenia
10. Gene variants may increase susceptibility to type 2 diabetes
11. Common gene variant increases risk of atherosclerosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
Breaking Biology Technology:
Cached News: